Atrial Fibrillation Drugs Market: 4 major trends fueling the industry share through 2025
The atrial fibrillation drugs market is forecasted to record lucrative growth on account of large presence of geriatric population base that is susceptible to valvular diseases. These drugs are effective against number of valvular diseases and are preferred by patients and doctors as an effective treatment option.
Growing inclination towards a sedentary lifestyle supported by proliferating habit of binge eating, specifically among millennials, could give rise to a series of valvular diseases, consequently driving the demand for atrial fibrillation medications. A research report by Global Market Insights, Inc., estimates that the atrial fibrillation drugs market could cross USD 17 billion by the year 2025.
According to a CDC report, in the U.S alone, nearly 2.5% of the entire population suffers from valvular heart disease, with rheumatic valvular heart disease accounting for nearly 3,046 deaths in 2017. Meanwhile, deaths due to non-rheumatic valvular heart disease amounted to 24,811 during the same period.
Listed below are some of the trends that may drive the demand for atrial fibrillation therapies:
Rising treatment demand across hospitals -
Hospitals are often considered as the most preferred healthcare facility for atrial fibrillation care in numerous countries around the world. Earlier in 2018, the hospital segment had attained a valuation of over USD 6,583.2 million.
Rising popularity of atrial fibrillation therapy in developed nations, sparked by increasing awareness on the availability of diverse drug therapies could accelerate the demand for atrial fibrillation drugs across hospitals.
Lucrative growth opportunities across the U.S. -
Growing presence of key industry players indulging various development activities could accelerate the atrial fibrillation drugs market growth in the U.S. The region has ample availability of efficient treatment options for atrial fibrillation. Stating an example, in 2020, medical device company, Medtronic announced clinical data on the use of Cryoballoon ablation device as a superior first-line treatment for paroxysmal atrial fibrillation (PAF) over other drug treatments.
Ascribed to numerous advancements, it is projected that the U.S. atrial fibrillation market could experience a 2.4% growth over 2026. Apart from new developments, mounting cases of chronic diseases like hypertension and diabetes could also broaden the business horizon for local players.
To access sample pages of this report titled, “Atrial Fibrillation Drugs Market Size By Products (Antiarrhythmic Drugs, Anticoagulant Drugs {Vitamin K Antagonists, Novel Oral Anticoagulants [Direct Thrombin Inhibitors, Direct Factor Xa Inhibitors]}), By Atrial Fibrillation Type (Paroxysmal, Persistent, Permanent), By Application (Heart Rhythm Control, Heart Rate Control) By Route of Administration (Oral, Injectable) By End-use (Hospitals, Cardiac Centres, Ambulatory Surgical Centres) Industry Analysis Report, Regional Outlook, Application Potential, Price Trends, Competitive Market Share & Forecast, 2019 – 2025” in detail along with the table of contents, please click on the link below:
https://www.gminsights.com/request-sample/detail/3253
Rising adoption across China -
China is a promising market for atrial fibrillation drug companies, as the industry was valued at USD 805.4 million in 2018. The Asian country struggles through high unmet health needs. As a result, it is slowly progressing towards developing more private clinics and engaging in the advancement of multi-specialty hospitals. Such initiatives could massively benefit the business prospects of atrial fibrillation treatment providers in China.
Adoption of favorable business strategies -
Prominent atrial fibrillation drugs market players like Pfizer, Johnson & Johnson, Bayer AG, Sanofi, Bristol-Myers Squibb, Boehringer Ingelheim, AstraZeneca, and Daiichi Sankyo are focusing on developing new solutions with enhanced functionality to enhance patient’s treatment outcomes. Companies are collaborating with other firms to develop new therapies as well as spread health awareness.
In 2020, Eliquis partnered with BMS and Pfizer to spread awareness and encourage people to seek prompt medical attention against three health conditions, namely atrial fibrillation, pulmonary embolism, and deep vein thrombosis.
About Global Market Insights, Inc.
Contact Us:
Arun Hegde
Corporate Sales, USA
Global Market Insights, Inc.
Phone: 1-302-846-7766
Toll Free: 1-888-689-0688
Email: sales@gminsights.com
Website: https://www.gminsights.com